The place of allogeneic stem cell transplantation in aggressive B-cell non-Hodgkin lymphoma in the era of CAR-T-cell therapy

被引：2
|
作者：
Castagna, Luca [1 ]
Bono, Roberto [1 ]
Tringali, Stefania [1 ]
Sapienza, Giuseppe [1 ]
Santoro, Alessandra [2 ]
Indovina, Alessandro [1 ]
Tarantino, Vittoria [3 ]
Di Noto, Laura [4 ]
Maggio, Aurelio [5 ]
Patti, Caterina [3 ]
机构：
[1] AOR Villa Sofia Vincenzo Cervello, BMT Unit, Palermo, Italy
[2] Azienda Ospedaliera Riun AOR Villa Sofia Vincenzo, Onco Hematol & Cell Manipulat Lab Unit, Palermo, Italy
[3] Azienda Ospedaliera Riun AOR Villa Sofia Vincenzo, Onco Hematol Unit, Palermo, Italy
[4] Azienda Ospedaliera Riun AOR Villa Sofia Vincenzo, Transfus & Transplantat Unit, Palermo, Italy
[5] Azienda Ospedaliera Riun AOR Villa Sofia Vincenzo, Campus Hematol Franco & Piera Cutino, Palermo, Italy
来源：
FRONTIERS IN MEDICINE | 2022年 / 9卷
关键词：
allogeneic stem cell transplantation; CAR-T cells therapy; non-Hodgkin lymphoma; refractory; toxicity; AXICABTAGENE CILOLEUCEL; CONDITIONING REGIMENS; INTERNATIONAL BLOOD; OPEN-LABEL; MULTICENTER; OUTCOMES; TISAGENLECLEUCEL; FLUDARABINE; RITUXIMAB; EFFICACY;
D O I：
10.3389/fmed.2022.1072192
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Chimeric antigen receptor T (CAR-T) cells are a treatment option for patients with relapse/refractory (R/R) non-Hodgkin lymphoma (NHL), acute lymphoid leukemia and multiple myeloma. To date, diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), follicular lymphoma (FL), and chronic lymphocytic leukemia (CLL) have been successfully treated with CAR-T cells directed against the CD19 antigen. However, when R/R disease persists after several treatment lines, patients with these diseases are often referred to transplantation centres to receive allogeneic stem cell transplantation (ALLO-SCT). ALLO-SCT and CAR-T cells share mechanism of actions, inducing immune effects of T-cells (and other cells after transplantation) against lymphoma cells, but they differ in several other characteristics. These differences justify unique positioning of each therapy within treatment algorithms. In this paper, we analyzed the results obtained after ALLO-SCT and CAR-T-cell therapy in patients with aggressive lymphomas (large B-cell lymphoma and MCL) to identify the ideal scenarios in which these 2 immunological therapies should be employed.
引用
收藏
页数：16
相关论文
共 50 条
  • [21] Autologous stem cell transplantation in aggressive non-Hodgkin's lymphoma
    Gisselbrecht, C
    ADVANCES IN HEMATOPOIETIC STEM CELL TRANSPLANTATION AND MOLECULAR THERAPY, 1998, 144 : 15 - 26
  • [22] Autologous stem cell transplantation in aggressive non-Hodgkin's lymphoma
    Gisselbrecht, C
    HEMATOLOGY AND CELL THERAPY, 1996, 38 (04) : 297 - 304
  • [23] Allogeneic Stem Cell Transplantation in Mantle Cell Lymphoma in the Era of New Drugs and CAR-T Cell Therapy
    Marangon, Miriam
    Visco, Carlo
    Barbui, Anna Maria
    Chiappella, Annalisa
    Fabbri, Alberto
    Ferrero, Simone
    Galimberti, Sara
    Luminari, Stefano
    Musuraca, Gerardo
    Re, Alessandro
    Zilioli, Vittorio Ruggero
    Ladetto, Marco
    CANCERS, 2021, 13 (02) : 1 - 21
  • [24] Stem cell transplantation in aggressive B-cell lymphoma
    Glass, B.
    ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 310 - 310
  • [25] Allogeneic haemopoietic stem cell transplantation for non-Hodgkin's lymphoma
    Toze, CL
    Barnett, MJ
    BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2002, 15 (03) : 481 - 504
  • [26] Outcomes of autologous or allogeneic stem cell transplantation for non-Hodgkin lymphoma
    Reddy, Nishitha M.
    Oluwole, Olalekan
    Greer, John P.
    Engelhardt, Brian G.
    Jagasia, Madan H.
    Savani, Bipin N.
    EXPERIMENTAL HEMATOLOGY, 2014, 42 (01) : 39 - 45
  • [27] The promise of CAR T-cell therapy in aggressive B-cell lymphoma
    Nair, Ranjit
    Neelapu, Sattva S.
    BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2018, 31 (03) : 293 - 298
  • [28] Autologous and Allogeneic Transplantation for Pediatric Mature B-Cell Non-Hodgkin Lymphoma in Japan
    Fujita, Naoto
    Kobayashi, Ryoji
    Atsuta, Yoshiko
    Mitsui, Tetsuo
    Iwasaki, Fuminori
    Suzumiya, Junji
    Sasahara, Yoji
    Inoue, Masami
    Koh, Katsuyoshi
    Sakamaki, Hisashi
    Yabe, Hiromasa
    Kawa, Keisei
    Kato, Koji
    Suzuki, Ritsuro
    BLOOD, 2014, 124 (21)
  • [29] Longitudinal analysis of CAR T-cell and immune cell populations in patients with aggressive B-cell non-Hodgkin Lymphoma: T-cell phenotypes predict the outcomes after CAR T-cell therapy
    Chitadze, G.
    Stuebig, T.
    Laqua, A.
    Nakov, P.
    Kehden, B.
    Khouja, M.
    Versteegen, T.
    Schroeder, T.
    Martens, T.
    Lohneis, A.
    Iaccarino, I.
    Klapper, W.
    Peipp, M.
    Klausz, K.
    Ritgen, M.
    Adam, S.
    Schuster, S. O.
    Fransecky, L.
    Valerius, T.
    Schub, N.
    Stoelzel, F.
    Brueggemann, M.
    Baldus, C. D.
    Pott, C.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 74 - 74
  • [30] Patient selection for chimeric antigen receptor (CAR) T-cell therapy for aggressive B-cell non-Hodgkin lymphomas
    Johnson, P. Connor
    Abramson, Jeremy S.
    LEUKEMIA & LYMPHOMA, 2020, 61 (11) : 2561 - 2567
12345